{"nctId":"NCT04852679","briefTitle":"Study to Assess the Efficacy and Safety of Lanreotide AutogelÂ® in Chinese Participants With GEP-NETs","startDateStruct":{"date":"2021-05-24","type":"ACTUAL"},"conditions":["Gastroenteropancreatic Neuroendocrine Tumor"],"count":43,"armGroups":[{"label":"lanreotide Autogel 120 mg","type":"OTHER","interventionNames":["Drug: Lanreotide autogel"]}],"interventions":[{"name":"Lanreotide autogel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Capable of giving signed informed consent\n* Male or female of 18 years of age or older when informed consent is obtained\n* Has a histologically proven Grade 1 or 2 GEP-NET according to WHO (World Health Organisation) classification\n* Has an unresectable metastatic or locally advanced NET.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status lower or equal to 2.\n\nExclusion Criteria:\n\n* Participants with poorly differentiated Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), high-grade GEP-NEC and goblet cell carcinoid.\n* Has been treated with octreotide acetate long-acting release or lanreotide acetate Autogel formulation within 8 weeks prior to screening tests or lanreotide PR 40 mg within 4 weeks prior to screening tests.\n* Has been treated with subcutaneous or intravenous octreotide acetate within 1 week prior to screening tests.\n* Has been treated with mammalian target of rapamycin (mTOR) inhibitors or multi-target tyrosine kinase (MTK) inhibitors within 4 weeks prior to screening tests.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Benefit Rate (CBR) of Tumour Response Assessed by Blinded Independent Central Review (BICR) at Week 24","description":"The CBR was defined as the percentage of participants with a best overall response of confirmed complete response (CR), confirmed partial response (PR), or continued stable disease (SD) until the time of assessment according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria v1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum longest diameter since the treatment started.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.79","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) by BICR Within Weeks 24 and 48","description":"The PFS was defined as the time from the first administration of study intervention to the date of the first documented PD measured using RECIST criteria v1.1 and confirmed by BICR, or death from any cause, whichever comes first. The PFS was estimated using the Kaplan-Meier method. The PD was defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) at the End of the Main Intervention Period","description":"The OS was defined as the time from the first administration of study intervention to the date of death from any cause. The OS was estimated using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Progression (TTP) During Main Intervention Period","description":"The TTP was defined as the time from the first administration of study intervention to the date of the first documented PD, or clinical progression confirmed by the investigator. The TTP was assessed by BICR and estimated using the Kaplan-Meier method. The PD was defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Alive and Without Tumour Progressive at Weeks 24 and 48","description":"Percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 24 and 48 weeks after first dose of study intervention were reported. The PFS was estimated using the Kaplan-Meier method. The PD was defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Benefit Rate Assessed by BICR at Week 48","description":"The CBR was defined as the percentage of participants with a best overall response of confirmed CR, confirmed PR, or continued SD until the time of assessment according to RECIST criteria v1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR) at Weeks 24 and 48","description":"The ORR was defined as the percentage of participants with a best overall response of confirmed CR or confirmed PR. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR) at Weeks 24 and 48","description":"The DCR was defined as the percentage of participants with a best overall response of confirmed CR, confirmed PR or SD. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. The SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Neuroendocrine Tumours (NET)-Related Clinical Symptoms at Weeks 24 and 48","description":"The presence or absence of endocrine symptoms of NETs (example; flushing, diarrhoea, abdominal pain, weakness, heartburn, nausea, vomiting, sweating, tremor, palpitation, or erythema) were assessed by the investigator at screening. In participants with symptoms of NETs at screening, a baseline assessment of the symptoms experienced in the last 4 weeks was performed by questioning before study intervention administration at Day 1. These symptoms were recorded in the case report form and severity graded upon National Cancer Institute Common Terminology Criteria for Adverse Events. Where, Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Plasma Chromogranin A (CgA) at Weeks 12, 24, 36 and 48","description":"The CgA determination was useful for staging, prognosis and follow up, since the serum concentration correlated to the tumour mass. Blood samples were collected to measure circulating CgA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.7305","spread":"105.1477"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.2278","spread":"126.1348"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.8435","spread":"125.4386"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.8557","spread":"134.5523"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 5-Hydroxyindoleacetic Acid (5-HIAA) at Weeks 12, 24, 36 and 48","description":"Urine samples were collected to measure 5-HIAA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5495","spread":"0.9598"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1965","spread":"4.5374"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0837","spread":"1.6261"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3129","spread":"6.3055"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life (QoL) Assessment at Weeks 12, 24, 36 and 48","description":"The European Organization for Research and Treatment of Cancer QoL Questionnaire for Cancer participants contains 30 single items. For questions 1 to 28, score ranges from 1 to 4 where, 1= not at all, 2= a little, 3= quite a bit and 4= very much. Global health status/QoL contains questions 29 and 30 and score ranges from 1 to 7, where 1= very poor and 7= excellent. Total score ranges from 0 (poor) to 100 (excellent). Higher score indicates a high QoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"16.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"18.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.4","spread":"16.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.8","spread":"19.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":43},"commonTop":["Diarrhoea","Alanine aminotransferase increased","Bilirubin conjugated increased","Blood bilirubin increased","Weight decreased"]}}}